LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 5 of 497
Next
>>
>
101 to 125 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	CGP60474	0.04	uM	LJP6	2	G06	72	hr	1657	1299	5505	0.2359	-0.0932
BT-20	CGP60474	0.04	uM	LJP6	3	G06	72	hr	1657	1187	5505	0.2156	-0.1223
BT-20	CHIR-99021	0.04	uM	LJP6	1	P18	72	hr	1657	5565	5505	1.0108	1.0154
BT-20	CHIR-99021	0.04	uM	LJP6	2	P18	72	hr	1657	5712	5505	1.0375	1.0536
BT-20	CHIR-99021	0.04	uM	LJP6	3	P18	72	hr	1657	5383	5505	0.9777	0.9681
BT-20	CP724714	0.04	uM	LJP5	1	A12	72	hr	1657	5545	5505	1.0071	1.0102
BT-20	CP724714	0.04	uM	LJP5	2	A12	72	hr	1657	4947	5505	0.8985	0.8548
BT-20	CP724714	0.04	uM	LJP5	3	A12	72	hr	1657	5131	5505	0.9320	0.9026
BT-20	CP466722	0.04	uM	LJP5	1	I12	72	hr	1657	5734	5505	1.0415	1.0593
BT-20	CP466722	0.04	uM	LJP5	2	I12	72	hr	1657	5960	5505	1.0825	1.1181
BT-20	CP466722	0.04	uM	LJP5	3	I12	72	hr	1657	6124	5505	1.1123	1.1607
BT-20	Crizotinib	0.04	uM	LJP5	1	A24	72	hr	1657	4480	5505	0.8137	0.7335
BT-20	Crizotinib	0.04	uM	LJP5	2	A24	72	hr	1657	4717	5505	0.8568	0.7950
BT-20	Crizotinib	0.04	uM	LJP5	3	A24	72	hr	1657	4650	5505	0.8446	0.7776
BT-20	Momelotinib	0.04	uM	LJP5	1	P12	72	hr	1657	4521	5505	0.8212	0.7441
BT-20	Momelotinib	0.04	uM	LJP5	2	P12	72	hr	1657	5377	5505	0.9766	0.9666
BT-20	Momelotinib	0.04	uM	LJP5	3	P12	72	hr	1657	4709	5505	0.8553	0.7930
BT-20	Dasatinib	0.04	uM	LJP5	1	D06	72	hr	1657	5244	5505	0.9525	0.9320
BT-20	Dasatinib	0.04	uM	LJP5	2	D06	72	hr	1657	5098	5505	0.9260	0.8941
BT-20	Dasatinib	0.04	uM	LJP5	3	D06	72	hr	1657	5126	5505	0.9310	0.9013
BT-20	Dasatinib	0.04	uM	LJP6	1	I06	72	hr	1657	3046	5505	0.5533	0.3608
BT-20	Dasatinib	0.04	uM	LJP6	2	I06	72	hr	1657	2804	5505	0.5093	0.2979
BT-20	Dasatinib	0.04	uM	LJP6	3	I06	72	hr	1657	2385	5505	0.4332	0.1890
BT-20	Dovitinib	0.04	uM	LJP5	1	E24	72	hr	1657	5189	5505	0.9425	0.9177
BT-20	Dovitinib	0.04	uM	LJP5	2	E24	72	hr	1657	4367	5505	0.7932	0.7041

|<
<<
Previous
Page 5 of 497
Next
>>
>
101 to 125 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 1 of 15: Cell count and relative growth within biological replicate 1. - Dataset (ID:20237)